Patents by Inventor Brian W. Grinnell
Brian W. Grinnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6545027Abstract: A method of modulating NF-kB transcription factor comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen, wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: June 7, 1995Date of Patent: April 8, 2003Assignee: Eli Lilly and CompanyInventors: David T. Berg, David S. Calnek, Brian W. Grinnell
-
Patent number: 6426071Abstract: A method of treatment for patients with vascular occlusion and thromboembolic disorders including the acquired disease state of thrombotic stroke, by administering activated protein C. The administration of aPC provides a highly selective therapeutic agent with a low potential for causing bleeding complications. The administration of aPC is beneficial in preventing the local extension of the microvascular and macrovascular occluding arterial thrombus, thereby reducing the neurological deficit resulting from the stroke.Type: GrantFiled: June 8, 2001Date of Patent: July 30, 2002Assignee: Eli Lilly and CompanyInventors: Brian W. Grinnell, Daniel C Howey, Charles V Jackson
-
Publication number: 20010036456Abstract: A method of treatment for patients with vascular occlusion and thromboembolic disorders including the acquired disease state of thrombotic stroke, by administering activated protein C. The administration of aPC provides a highly selective therapeutic agent with a low potential for causing bleeding complications. The administration of aPC is beneficial in preventing the local extension of the microvascular and macrovascular occluding arterial thrombus, thereby reducing the neurological deficit resulting from the stroke.Type: ApplicationFiled: June 8, 2001Publication date: November 1, 2001Inventors: Brian W. Grinnell, Daniel C. Howey, Charles V. Jackson
-
Patent number: 6268337Abstract: A method of treatment for patients with vascular occlusion and thromboembolic disorders including the acquired disease state of thrombotic stroke, by administering activated protein C. The administration of aPC provides a highly selective therapeutic agent with a low potential for causing bleeding complications. The administration of aPC is beneficial in preventing the local extension of the microvascular and macrovascular occluding arterial thrombus, thereby reducing the neurological deficit resulting from the stroke.Type: GrantFiled: December 16, 1999Date of Patent: July 31, 2001Assignee: Eli Lilly and CompanyInventors: Brian W. Grinnell, Daniel C Howey, Charles V Jackson
-
Patent number: 6242192Abstract: The present invention is a method of using the BK enhancer in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.Type: GrantFiled: March 9, 2000Date of Patent: June 5, 2001Assignee: Eli Lilly and CompanyInventor: Brian W. Grinnell
-
Patent number: 6057130Abstract: The present invention is a method of using the BK enhancer in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.Type: GrantFiled: October 16, 1998Date of Patent: May 2, 2000Assignee: Eli Lilly and CompanyInventor: Brian W. Grinnell
-
Patent number: 6037322Abstract: A method of treatment for patients with vascular occlusion and thromboembolic disorders including the acquired disease state of thrombotic stroke, by administering activated protein C. The administration of aPC provides a highly selective therapeutic agent with a low potential for causing bleeding complications. The administration of aPC is beneficial in preventing the local extension of the microvascular and macrovascular occluding arterial thrombus, thereby reducing the neurological deficit resulting from the stroke.Type: GrantFiled: September 28, 1998Date of Patent: March 14, 2000Assignee: Eli Lilly and CompanyInventors: Brian W. Grinnell, Daniel C Howey, Charles V Jackson
-
Patent number: 5879919Abstract: The present invention is a method of using the BK enhancer in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.Type: GrantFiled: April 8, 1998Date of Patent: March 9, 1999Assignee: Eli Lilly and CompanyInventor: Brian W. Grinnell
-
Patent number: 5858704Abstract: The present invention is a method of using the BK enhancer in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.Type: GrantFiled: June 2, 1995Date of Patent: January 12, 1999Assignee: Eli Lilly and CompanyInventor: Brian W. Grinnell
-
Patent number: 5770397Abstract: The present invention is a method of using the BK enhancer in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.Type: GrantFiled: June 2, 1995Date of Patent: June 23, 1998Assignee: Eli Lilly and CompanyInventor: Brian W. Grinnell
-
Patent number: 5700815Abstract: A method of increasing thrombomodulin expression comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl;R.sup.2 is selected from the group consisting of pyrrolidino, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.whereinR.sup.1 and R.sup.3 are independently hydrogen, ##STR3## wherein Ar is optionally substituted phenyl;R.sup.2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof.Also encompassed by the invention is a method of inhibiting a thrombotic disorder or event which includes administering to a human in need thereof an effective amount of a compound of formula 1.Type: GrantFiled: August 21, 1995Date of Patent: December 23, 1997Assignee: Eli Lilly and CompanyInventors: David S. Calnek, Brian W. Grinnell
-
Patent number: 5681932Abstract: The present invention is a method of using the BK enhances in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.Type: GrantFiled: June 2, 1995Date of Patent: October 28, 1997Assignee: Eli Lilly and CompanyInventor: Brian W. Grinnell
-
Patent number: 5661002Abstract: The present invention is a modified transcription control unit which contains the P2 enhancer of BK virus spaced closely to the upstream regulatory element of the major late promoter of adenovirus, the adenovirus-2 major late promoter, a poly-GT element positioned to stimulate said promoter and a DNA sequence containing the spliced tripartite leader sequence of adenovirus. The invention further comprises methods of using this modified transcription unit in cells expressing the adenovirus E1A gene product to produce useful substances. The invention further comprises methods to increase the levels of expression in stably transformed cells by performing a second transformation with a vector containing the modified transcription unit.Type: GrantFiled: May 19, 1995Date of Patent: August 26, 1997Assignee: Eli Lilly and CompanyInventors: David T. Berg, Brian W. Grinnell
-
Patent number: 5658788Abstract: The present invention provides derivatives of tissue plasminogen activator that lack the Finger, Growth Factor and Kringle 1 domains and comprise a Kringle 2 domain that is monoglycosylated at a site other than that of t-PA. Using recombinant DNA techniques, an alternate glycosylation sequence is provided within the Kringle 2 domain of these t-PA derivatives. This alternate glycosylation consensus sequence, as well as the glycosylation consensus sequence within the Serine Protease domain, is glycosylated upon the expression and secretion of these molecules from eucaryotic host cells. Thus, a homogeneous population of diglycosylated t-PA derivatives that lack the Finger, Growth Factor and Kringle 1 domains is produced.Type: GrantFiled: April 21, 1995Date of Patent: August 19, 1997Assignee: Eli Lilly and CompanyInventors: David T. Berg, Brian W. Grinnell
-
Patent number: 5618714Abstract: The present invention relates to a method for producing high levels of functional recombinant proteins in adenovirus-transformed mammalian cells by incubating cells capable of producing recombinant proteins at a temperature range between about 38 degrees centigrade and about 39 degrees centigrade. The method allows for higher levels of expression of total protein in some cell lines and higher levels of functional protein in other cell lines.Type: GrantFiled: December 15, 1993Date of Patent: April 8, 1997Assignee: Eli Lilly and CompanyInventor: Brian W. Grinnell
-
Patent number: 5595736Abstract: The present invention provides derivatives of tissue plasminogen activator that lack the Finger, Growth Factor and Kringle 1 domains and comprise a Kringle 2 domain that is monoglycosylated at a site other than that of t-PA. Using recombinant DNA techniques, an alternate glycosylation sequence is provided within the Kringle 2 domain of these t-PA derivatives. This alternate glycosylation consensus sequence, as well as the glycosylation consensus sequence within the Serine Protease domain, is glycosylated upon the expression and secretion of these molecules from eucaryotic host cells. Thus, a homogeneous population of diglycosylated t-PA derivatives that lack the Finger, Growth Factor and Kringle 1 domains is produced.Type: GrantFiled: March 27, 1995Date of Patent: January 21, 1997Assignee: Eli Lilly and CompanyInventors: David T. Berg, Brian W. Grinnell
-
Patent number: 5578465Abstract: The present invention is a method of using the BK enhancer in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.Type: GrantFiled: June 2, 1995Date of Patent: November 26, 1996Assignee: Eli Lilly and CompanyInventor: Brian W. Grinnell
-
Patent number: 5573938Abstract: The present invention is a modified transcription control unit which contains the P2 enhancer of BK virus spaced closely to the upstream regulatory element of the major late promoter of adenovirus, the adenovirus-2 major late promoter, a poly-GT element positioned to stimulate said promoter and a DNA sequence containing the spliced tripartite leader sequence of adenovirus. The invention further comprises methods of using this modified transcription unit in cells expressing the adenovirus E1A gene product to produce useful substances. The invention further comprises methods to increase the levels of expression in stably transformed cells by performing a second transformation with a vector containing the modified transcription unit.Type: GrantFiled: December 1, 1993Date of Patent: November 12, 1996Assignee: Eli Lilly and CompanyInventors: David T. Berg, Brian W. Grinnell
-
Patent number: RE37720Abstract: The present invention is a method of using the BK enhancer in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.Type: GrantFiled: August 26, 1999Date of Patent: May 28, 2002Assignee: Eli Lilly and CompanyInventor: Brian W. Grinnell
-
Patent number: RE37806Abstract: The present invention is a method of using the BK enhances in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene produce for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.Type: GrantFiled: August 26, 1999Date of Patent: July 23, 2002Assignee: Eli Lilly and CompanyInventor: Brian W. Grinnell